Nottingham, UK (2 August 2010) Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has signed a supply agreement for albucult, recombinant albumin with one of the world’s leading manufacturers of medical disposables for open heart surgery. This agreement will result in the launch of the first Class III medical device containing albucult.
Novozymes Biopharma has supplied animal-free, recombinant human albumin to this leading manufacturer for over 10 years and this new agreement solidifies the already successful partnership between the two companies. Derived from Novozymes Biopharma’s proprietary yeast expression technology, albucult delivers unprecedented performance and quality benefits to medical applications including device coating, sealants, and cell therapy applications.
Class III devices are highly regulated and used in ‘high risk’ applications such as pacemakers and heart valves. The use of albucult within such medical devices offers a range of unique advantages including sustainability of supply, GMP compliance and improved biocompatibility. albucult also offers batch-to-batch consistency which can significantly reduce lot testing burdens for clients.
“Novozymes Biopharma is pleased to consolidate its position in the medical device market with the signing of this long-term agreement”, says Dermot Pearson, Marketing Director, Novozymes Biopharma. “This continued partnership demonstrates Novozymes’ strength and extensive understanding of manufacturing, regulatory and global supply, making the company an ideal partner to work with. It is a great achievement for albucult to be used for the first time within a Class III medical device product and is a real testament to the quality and innovation of the products that we are developing.”
For further information on albucult please visit www.biopharma.novozymes.com
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers’ business and the use of our planet’s resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.
Novozymes’ natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Contacts: Novozymes Biopharma: Sally Vernon, Customer Communications Manager SYKE@novozymes.com Tel. +44 115 955 3355
Corporate Contacts: Press and media: Johan Melchior Tel. (direct): +45 4446 0690 Tel. (mobile): +45 3077 0690
René Tronborg Tel. (direct): +45 4446 2274 Tel. (mobile): +45 3077 2274
Paige Donnelly (USA) Tel. (direct): +1 919 494 3209 Tel. (mobile): +1 919 218 4501
Investor relations: Tobias Bjørklund Tel. (direct): +45 4446 8682 Tel. (mobile): +45 3077 8682
Thomas Steenbech Bomhoff (USA) Tel. (direct): +1 919 494 3483 Tel. (mobile): +1 919 649 2565
Michelle Valentine The Scott Partnership Ltd 1 Whiteside Station Road Holmes Chapel Cheshire CW4 8AA UK Tel: +44 1477 539539 Fax: +44 1477 539540 Email: msv@scottpr.com Web: www.scottpr.com
